Short-term reductions in the probability of disease recurrence associated with adding bevacizumab to an adjuvant chemotherapy regimen for patients with early TNBC were projected to improve quality-adjusted survival and potentially be cost-effective given recent discussions concerning willingness-to-pay thresholds in the UK.
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COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN
Liu PH, Wang JD National Taiwan University, College of Public Health, Taipei, Taiwan OBJECTIVES: Human papillomavirus (HPV) infection had been demonstrated as a major risk factor for cervical cancer. Vaccines against HPV-16 and HPV-18 appeared highly effi cacious in preventing HPV-16 and HPV-18 infections and cervical lesions including cervical cancer. However, only limited available data described the health and economic implications of HPV vaccination in Taiwan. The objective of this study was to assess the cost-effectiveness of prophylactic HPV vaccination for prevention of cervical cancer in Taiwan. METHODS: We developed a Markov model to compare the health and economic outcomes of vaccinating preadolescent girls (at age of 12 years old) for prevention of cervical cancer with current practice. Data were synthesized from published papers, and whenever possible, those specifi c to Taiwan were used. The economic analysis adopted the health care payer's perspective, and only direct medical costs were taken into account. Sensitivity analyses were performed to account for important uncertainties and different vaccination scenario. RESULTS: Under the assumption that the HPV vaccine would provide lifelong protection, vaccination among preadolescent girls in Taiwan would result in a life expectancy gain of 16.8 days or 21.2 quality-adjusted life days at a cost of US$287 as compared with the current screening practice. The incremental cost-effectiveness ratio (ICER) was US$6,236 per life year gained or US$4,946 per QALY gained given the discount rate of 3%. Sensitivity analyses showed that this ICER would remain far below US$30,000 per QALY even when vaccine compliance was unsatisfactory or vaccine-induced immunity wanned that needed booster shot. CONCLUSIONS: Although gains in life expectancy may be modest at individual level, the results indicate that prophylactic HPV vaccination on preadolescent girls in Taiwan would result in substantial population benefi ts, i.e., it is a very cost-effective strategy in public health.
PCN54 COST-MINIMIZATION ANALYSIS OF FLUDARABINE ASSOCIATED TO ALEMTUZUMAB (FLUCAM) VERSUS THE ASSOCIATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE SECOND LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Teich N 1 , Teich V 1 , Benitez R 1 , Schiola A 2 1 MedInsight, Rio de Janeiro, Brazil, 2 Bayer Schering Pharma Brazil, São Paulo, Brazil OBJECTIVES: The objective of the study was to compare the effi cacy and treatment costs of FLUCAM versus FCR in the second line treatment of CLL in a one year time horizon under the Brazilian private health care system (BPS) perspective. METHODS: A literature review was performed and two phase II trials were found, evaluating the effi cacy of FLUCAM (JCO 2005; 23:7024) or FCR (JCO 2005; 23:4070) . FLUCAM presented higher response rates and lower overall survival and time to disease progression than FCR. Grouping patients from both studies into risk groups, and assuming median overall survivals of 11, 6 and 2 years for low, intermediate and high risk patients, respectively, resulted in an expected median overall survival of 2.89 years for FLUCAM and 4.15 years for FCR. This refl ects the higher disease severity in the FLUCAM study population at baseline. Therefore, it cannot be concluded through an indirect comparison that one treatment is superior to the other. Assuming equivalent effi cacies for both treatments, a cost-minimization analysis was developed. Study protocols were valued considering an average body surface of 1.7m2 and maximum prices to consumer for drugs. Antimicrobial prophylaxis and pre-treatment drugs were included. The average number of cycles administered was 4.2 cycles for both protocols. Dose reductions were considered for FCR. Eighty-six of patients have received normal dosage, 13% had a level 1 dose reduction starting on the third cycle, and 1% had a Level 1 reduction at Cycle 3 and a Level 2 reduction from Cycle 4. RESULTS: Treatment costs found in one year were R$36,370 for FLUCAM and R$63,778 for FCR, representing a cost reduction of R$27,408 (US$11,874) in favor of FLUCAM. CONCLUSIONS: Assuming equivalent effi cacies for both treatments, FLUCAM presented a lower total treatment cost than FCR, being a valuable alternative in face of budget constraints, for the BPS. This burden of illness study was conducted to assess the 12-month resource utilization and health care costs, along with the major drivers of those costs, associated with an incident diagnosis of breast cancer (BC). METHODS: An analysis of incident BC patients identifi ed using a claims database, was performed, for 2005, 2006, and 2007 . BC patients and the age and gender matched comparator group (1:4) for each year, were required to have continuous enrollment in a plan and no breast cancer diagnoses during the 18 months prior to the fi rst diagnosis of breast cancer in the year. The BC and comparison groups were each described in terms of their health care service use and health care costs, which were compared, using nonparametric The signifi cantly higher 12-month resource utilization and health care costs noted in women diagnosed with BC, compared to age and gender matched controls, are primarily driven by an increased need for prescription drugs, hospitalizations, radiology tests, and laboratory tests.
PCN55 ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH BREAST CANCER
PCN56 IMPACT OF BONE METASTASES (BM) ON HEALTH CARE COSTS BEFORE AND AFTER OCCURRENCE OF SKELETAL RELATED EVENTS (SRES) IN MEN WITH PROSTATE CANCER (PC)
Oglesby A g y 1 , Delea T 2 , Hagiwara M 2 , Zilber S 2 , Berger A 2 1 Amgen, Inc., Thousand Oaks, CA, USA, 2 Policy Analysis Inc. (PAI), Brookline, MA, USA OBJECTIVES: Clinical trial results suggest that patients with PC BM may experience SREs an average of 16 months after the BM diagnosis. Prior studies examined the cost of SREs in patients with PC BM but have not evaluated the period from BM diagnosis to development of SREs. We examined costs in men with PC BM before and after the occurrence of SREs. METHODS: This study used claims data from a large, U.S. health insurance plan spanning January 2003-December 2007. Patients were included in the analysis if they were male and had: diagnoses of PC and BM, at least one claim for hormonal therapy (HT) in the year prior to BM, a complete claims history and no claims for malignancy in the year prior to BM diagnosis. SREs were identifi ed based on CPT/ICD-9 codes and included radiotherapy, pathological fracture, surgery to the bone, spinal cord compression, or hypercalcemia. The impact of BM and SREs on total health care costs (i.e. inpatient, outpatient, pharmacy) for the period six months prior to BM ending with disenrollment or end of the study period was evaluated using repeated-measures generalized linear model regression. RESULTS: Of 216,554 PC patients, 10,520 had a diagnosis of BM, with 4,988 receiving HT in the year prior to BM. Of these, 1385 met all inclusion criteria, including 652 (47%) with 1 SRE and 733 with no SRE (53%). Mean total health care costs were $23,481/ person-year (PY) in the 6 months prior to BM. On an adjusted basis, costs increase by $5,722/PY with BM and no SREs (p 0.001) and by $17,202/PY with BM and SREs (p 0.001). BM without SREs was associated with 91% increase in hospitalization risk; BM with SREs, a 181% increase in hospitalization risk. CONCLUSIONS: BM are associated with increased total health care costs, even in the absence of SREs in patients with PC.
